XNAS
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
The standout catalyst is Regeneron’s $75M private placement at **90% of the IPO price**, a strong validation of Parabilis’ pipeline. But Q2 was effectively pre-commercial, with **$148K revenue** and a **$2.32 EPS loss**, so near-term fundamentals remain highly speculative.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.23 | -2.32 | -908.70% | $148,000 | ❌ Miss | +0.00% | +10.96% | — |
Showing last 1 quarters.